1
|
Inwards DJ, Fishkin PA, LaPlant BR, Drake MT, Kurtin PJ, Nikcevich DA, Wender DB, Lair BS, Witzig TE. Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. Ann Oncol 2019; 30:346. [PMID: 29390098 PMCID: PMC6386023 DOI: 10.1093/annonc/mdx814] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
2
|
Inwards DJ, Fishkin PA, LaPlant BR, Drake MT, Kurtin PJ, Nikcevich DA, Wender DB, Lair BS, Witzig TE. Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. Ann Oncol 2014; 25:2020-2024. [PMID: 25057177 DOI: 10.1093/annonc/mdu273] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND We conducted this trial to determine the maximum tolerated dose (MTD) of temsirolimus added to an established regimen comprised of rituximab and cladribine for the initial treatment of mantle cell lymphoma. PATIENTS AND METHODS A standard phase I cohort of three study design was utilized. The fixed doses of rituximab and cladribine were 375 mg/m(2) i.v. day 1 and 5 mg/m(2)/day i.v. days 1-5 of a 28-day cycle, respectively. There were five planned temsirolimus i.v. dose levels: 15 mg day 1; 25 mg day 1; 25 mg days 1 and 15; 25 mg days 1, 8 and 15; and 25 mg days 1, 8, 15, and 22. RESULTS Seventeen patients were treated: three each at levels 1-4 and five at dose level 5. The median age was 75 years (52-86 years). Mantle Cell International Prognostic Index (MIPI) scores were low in 6% (1), intermediate in 59% (10), and high in 35% (6) of patients. Five patients were treated at level 5 without dose limiting toxicity. Hematologic toxicity was frequent: grade 3 anemia in 12%, grade 3 thrombocytopenia in 41%, grade 4 thrombocytopenia in 24%, grade 3 neutropenia in 6%, and grade 4 neutropenia in 18% of patients. The overall response rate (ORR) was 94% with 53% complete response and 41% partial response. The median progression-free survival was 18.7 months. CONCLUSIONS Temsirolimus 25 mg i.v. weekly may be safely added to rituximab and cladribine at 375 mg/m(2) i.v. day 1 and 5 mg/m(2)/day i.v. days 1-5 of a 28-day cycle, respectively. This regimen had promising preliminary activity in an elderly cohort of patients with mantle cell lymphoma. CLINICALTRIALSGOV IDENTIFIER NCT00787969.
Collapse
Affiliation(s)
- D J Inwards
- Division of Hematology, Mayo Clinic, Rochester.
| | - P A Fishkin
- Illinois Oncology Research Association, Peoria
| | - B R LaPlant
- Division of Endocrinology, Mayo Clinic, Rochester
| | - M T Drake
- Division of Endocrinology, Mayo Clinic, Rochester
| | - P J Kurtin
- Division of Hematopathology, Mayo Clinic, Rochester
| | - D A Nikcevich
- Department of Medical Oncology, Essentia Duluth Clinic, Duluth
| | - D B Wender
- Department of Oncology, Siouxland Hematology-Oncology Associates, Sioux City
| | - B S Lair
- Department of Oncology, Iowa Oncology Research Association, Des Moines, USA
| | - T E Witzig
- Division of Hematology, Mayo Clinic, Rochester
| |
Collapse
|
3
|
Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Dakhil SR, Loprinzi CL. Does tetracycline prevent/palliate epidermal growth factor receptor (EGFR) inhibitor-induced rash? A phase III trial from the North Central Cancer Treatment Group (N03CB). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.lba9006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA9006 Purpose: Many patients who receive EGFR inhibitors develop an acneiform rash, and anecdotal reports suggest tetracycline is effective in treating it. To our knowledge, however, no rigorous trials have ever been published to substantiate this approach. This double- blinded, placebo-controlled trial was conducted to assess the role of tetracycline in preventing EGFR inhibitor-induced rash and/or reducing its severity. Methods: 61 patients were randomly assigned to tetracycline 500 mg orally twice a day×4 weeks versus an identical, similarly prescribed placebo. Eligibility criteria required all patients to have begun an EGFR inhibitor </= 7 days prior with no rash at study entry. Patients were to be followed for 8 weeks. Physician assessments of rash incidence, severity, and adverse events, occurred at 4 and 8 weeks. Patients completed a weekly rash diary, quality of life questionnaire (SKINDEX-16), and EGFR inhibitor compliance questionnaire. Thirty patients per group provides 90% power to detect a difference in rash incidence (the primary endpoint) of 40% between groups and of rejecting the null hypothesis of equal proportions with a type I error of 5% (2-sided). Results: Treatment arms were balanced on baseline characteristics, drop out rates, and rates of discontinuation of the EGFR inhibitor. Rash incidence was comparable across arms. Physicians reported that 16 tetracycline-treated patients (70%) and 22 placebo-exposed patients (76%) developed a rash (p=0.61). However, tetracycline appears to have lessened rash severity. By week 4, physician-reported grade 2 rash occurred in 17% of tetracycline-treated patients (n=4) and 55% of placebo- exposed patients (n=16); (p=0.04). Tetracycline-treated patients reported better scores on certain quality of life parameters (SKINDEX-16), such as skin burning or stinging, skin irritation, and being bothered by a persistence/recurrence of a skin condition. Adverse events were comparable across arms. Conclusion: Tetracycline did not prevent EGFR inhibitor-induced rashes. However, diminished rash severity and improved quality of life suggest this antibiotic merits further study. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Jatoi
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - K. Rowland
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - J. A. Sloan
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - H. M. Gross
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - P. A. Fishkin
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - S. P. Kahanic
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - P. J. Novotny
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - P. L. Schaefer
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - S. R. Dakhil
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - C. L. Loprinzi
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| |
Collapse
|
4
|
Inwards DJ, Hillman DW, Fishkin PA, White WL, Morton RF, Dakhil SR, Nikcevich DA, Wender DB, Fitch TR, Kurtin PJ. Phase II study of rituximab and cladribine (2-CDA) in newly diagnosed mantle cell lymphoma (MCL) (N0189). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.17505] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17505 Background: A previous trial of 2-CDA as a single agent for therapy of mantle cell lymphoma demonstrated this agent to be efficacious with an overall response rate of 81% (31% complete responses) (Blood 1999 Nov 15; 94:660a). A phase II study of the addition of rituximab to 2-CDA was conducted by the North Central Cancer Treatment Group based on improved outcomes achieved by the addition of rituximab to other regimens active in MCL. Methods: This one-stage phase II study was designed to determine the complete response (CR) or complete response/unconfirmed (CRu) rate. Central pathology confirmation of cyclin D1 positive mantle cell lymphoma was required. No previous therapy for lymphoma was allowed, with the exception of splenectomy. The shedule was rituximab 375 mg/m2 IV day 1; 2-CDA 5 mg/m2/d IV days 1–5 of a 4-week cycle. After 2 of the first 6 patients developed grade 4 neutropenia, subsequent patients received either pegfilgrastim or filgrastim support. Patients received 2–6 cycles of therapy, depending on response. Patients were required to achieve at least a PR after 2 cycles of therapy to continue on protocol therapy. Results: Patient characteristics of all 29 eligible pts: median age: 70 (range: 41–86); 21 male, 8 female; PS 0 (55.2%), PS 1 (41.4%), PS 2 (3.5%); stage II (6.9%), stage III (3.5%), stage IV (89.7%); prior splenectomy (20.7%). The only grade 4 adverse event occurring more than once was neutropenia (20.7%). One patient died of cerebral ischemia in the setting of pneumonia without neutropenia. Response has been determined in 26 pts with 50.0% (95% CI: 30.0–70.0%) achieving a CR, none of whom have relapsed to date. Three patients progressed early at 17, 45, and 46 days, two of whom have died, and a fourth relapsed day 222. 10 pts (34.0%) went on to receive further therapy off study, 5 in less than a PR after 2 cycles, 2 in PR after study therapy, and 1 who went off study for a rash. At last contact, 26 (89.7%) were alive (median follow-up 10.7 months; range: 1–28). Conclusions: Rituximab and cladribine were well tolerated for the treatment of MCL in a group including elderly patients. The response rate may have been underestimated due to the study design, which required at least a PR after 2 cycles to continue therapy. Despite this, 50% achieved a complete remission. [Table: see text]
Collapse
Affiliation(s)
- D. J. Inwards
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association, Peoria, IL; Medical Oncology and Hematology Associates, Des Moines, IA; Witchita CCOP, Witchita, KS; Duluth Clinic, Duluth, MN; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Scottsdale, AZ
| | - D. W. Hillman
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association, Peoria, IL; Medical Oncology and Hematology Associates, Des Moines, IA; Witchita CCOP, Witchita, KS; Duluth Clinic, Duluth, MN; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Scottsdale, AZ
| | - P. A. Fishkin
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association, Peoria, IL; Medical Oncology and Hematology Associates, Des Moines, IA; Witchita CCOP, Witchita, KS; Duluth Clinic, Duluth, MN; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Scottsdale, AZ
| | - W. L. White
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association, Peoria, IL; Medical Oncology and Hematology Associates, Des Moines, IA; Witchita CCOP, Witchita, KS; Duluth Clinic, Duluth, MN; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Scottsdale, AZ
| | - R. F. Morton
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association, Peoria, IL; Medical Oncology and Hematology Associates, Des Moines, IA; Witchita CCOP, Witchita, KS; Duluth Clinic, Duluth, MN; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Scottsdale, AZ
| | - S. R. Dakhil
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association, Peoria, IL; Medical Oncology and Hematology Associates, Des Moines, IA; Witchita CCOP, Witchita, KS; Duluth Clinic, Duluth, MN; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Scottsdale, AZ
| | - D. A. Nikcevich
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association, Peoria, IL; Medical Oncology and Hematology Associates, Des Moines, IA; Witchita CCOP, Witchita, KS; Duluth Clinic, Duluth, MN; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Scottsdale, AZ
| | - D. B. Wender
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association, Peoria, IL; Medical Oncology and Hematology Associates, Des Moines, IA; Witchita CCOP, Witchita, KS; Duluth Clinic, Duluth, MN; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Scottsdale, AZ
| | - T. R. Fitch
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association, Peoria, IL; Medical Oncology and Hematology Associates, Des Moines, IA; Witchita CCOP, Witchita, KS; Duluth Clinic, Duluth, MN; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Scottsdale, AZ
| | - P. J. Kurtin
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association, Peoria, IL; Medical Oncology and Hematology Associates, Des Moines, IA; Witchita CCOP, Witchita, KS; Duluth Clinic, Duluth, MN; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Scottsdale, AZ
| |
Collapse
|
5
|
Siebert JD, Harvey LA, Fishkin PA, Knost JA, Ehsan A, Smir BN, Craig FE. Comparison of lymphoid neoplasm classification. A blinded study between a community and an academic setting. Am J Clin Pathol 2001; 115:650-5. [PMID: 11345827 DOI: 10.1309/84vg-pl1v-t547-vc2r] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Abstract
The revised European-American classification of lymphoid neoplasms has been reported as reproducible among expert pathologists and feasible in a community setting. We evaluated the reproducibility of lymphoid neoplasm diagnoses between a community and an academic center. We subtyped 188 lymphoid neoplasms using revised European-American classification criteria. Clinical findings, histologic or cytologic preparations, paraffin-section immunostains, and flow cytometry data were reviewed as appropriate. Diagnoses were compared only after completion of the study. Lymphoma subtype was concordant for 167 (88.8%) of 188 cases. Discordant cases included 15 B-cell, 2 T-cell, and 4 Hodgkin lymphomas. For B-cell neoplasms, discordance was most often due to classifying diffuse large cell lymphoma as another aggressive subtype of lymphoma (n = 6), marginal zone lymphoma as another subtype (n = 4), or follicle center lymphoma grade II as grade III (n = 3). For Hodgkin disease, discordance was most often due to classifying nodular sclerosis as mixed cellularity type (n = 3). Comparison of community and academic center diagnoses demonstrated high concordance for most revised European-American classification subtypes. Some sources of discordance have been addressed in the new World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues.
Collapse
Affiliation(s)
- J D Siebert
- Department of Pathology, OSF Saint Francis Medical Center, 530 NE Glen Oak Ave, Peoria, IL 61637, USA
| | | | | | | | | | | | | |
Collapse
|
6
|
Siebert JD, Weeks LM, List LW, Kugler JW, Knost JA, Fishkin PA, Goergen MH. Utility of flow cytometry immunophenotyping for the diagnosis and classification of lymphoma in community hospital clinical needle aspiration/biopsies. Arch Pathol Lab Med 2000; 124:1792-9. [PMID: 11100059 DOI: 10.5858/2000-124-1792-uofcif] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
CONTEXT Flow cytometry immunophenotyping (FC) of needle aspiration/biopsy (NAB) samples has been reported to be useful for the diagnosis and classification of lymphoma in university and cancer center-based settings. Nevertheless, there is no agreement on the utility of these methods. OBJECTIVE To further define the utility of adjunctive FC of clinical NAB for the diagnosis and classification of lymphoma, and to determine if this approach is practicable in a routine clinical practice setting. SETTING A community-based hospital. METHODS Clinical NABs were submitted for adjunctive FC between June 1996 and September 1999 if initial smears were suspicious for lymphoma. Smears and cell block or needle core tissues were routinely processed and paraffin-section immunostains were performed if indicated. The final diagnosis was determined by correlating clinical and pathologic data, and the revised European-American classification criteria were used to subtype lymphomas. RESULTS Needle aspiration/biopsies from 60 different patients were submitted for FC. Final diagnoses were lymphoma (n = 38), other neoplasm (n = 15), benign (n = 6), or insufficient (n = 1). For 38 lymphomas (20 primary, 18 recurrent), patients ranged in age from 32 to 86 years (mean, 62 years); samples were obtained from the retroperitoneum (n = 11), lymph node (n = 9), abdomen (n = 8), mediastinum (n = 6), or other site (n = 4); and lymphoma subtypes were indolent B-cell (n = 20; 2 small lymphocytic, 14 follicle center, 4 not subtyped), aggressive B-cell (n = 14; 3 mantle cell, 10 large cell, 1 not subtyped), B-cell not further specified (n = 2), or Hodgkin disease (n = 2). For the diagnosis of these lymphomas, FC was necessary in 20 cases, useful in 14 cases, not useful in 2 cases, and misleading in 2 cases. Thirty-two of 36 lymphoma patients with follow-up data received antitumor therapy based on the results of NAB plus FC. CONCLUSIONS Adjunctive FC of NABs is potentially practicable in a community hospital, is necessary or useful for the diagnosis and subtyping of most B-cell lymphomas, and can help direct lymphoma therapy. Repeated NAB or surgical biopsy is necessary for diagnosis or treatment in some cases.
Collapse
Affiliation(s)
- J D Siebert
- Department of Pathology, OSF Saint Francis Medical Center, Peoria, IL 61637, USA
| | | | | | | | | | | | | |
Collapse
|
7
|
Siebert JD, Mulvaney DA, Potter KL, Fishkin PA, Geoffroy FJ. Relative frequencies and sites of presentation of lymphoid neoplasms in a community hospital according to the revised European-American classification. Am J Clin Pathol 1999; 111:379-86. [PMID: 10078114 DOI: 10.1093/ajcp/111.3.379] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Relative frequencies for common subtypes in the revised European-American classification of lymphoid neoplasms (REAL classification) have been reported. We determined the relative frequencies and sites of presentation of REAL subtypes at a 700-bed community hospital in central Illinois. A database was used to identify and prospectively catalogue all newly diagnosed lymphoid neoplasms from July 1, 1995 to March 1, 1998. The approach to diagnosis and subtyping incorporated morphologic features, immunophenotype, and clinical findings according to criteria proposed in the REAL classification. Of 347 lymphoid neoplasms diagnosed, 319 were subtyped in the REAL classification. Of these, 261 were B-cell neoplasms, 21 were T-cell neoplasms, and 37 were Hodgkin disease variants. Chronic lymphocytic leukemia/small lymphocytic lymphoma/prolymphocytic leukemia, diffuse large cell, and follicle center neoplasms were the most common B-cell subtypes. Large granular lymphocyte leukemia was the most common T-cell neoplasm. Nodular sclerosis was the most common Hodgkin disease variant. The relative frequencies in a US community hospital setting are similar to those reported in other studies. Differences are attributable to patient selection criteria, study group geographic location and racial composition, and/or referral patterns. Diverse REAL classification subtypes may be expected in US community hospitals.
Collapse
Affiliation(s)
- J D Siebert
- OSF Saint Francis Medical Center, Peoria, Illinois, USA
| | | | | | | | | |
Collapse
|
8
|
Vokes EE, Ansari RH, Masters GA, Hoffman PC, Klepsch A, Ratain MJ, Sciortino DF, Lad TE, Krauss S, Fishkin PA, Golomb HM. A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer. Ann Oncol 1998; 9:1085-90. [PMID: 9834820 DOI: 10.1023/a:1008432729754] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND 9-Aminocamptothecin (9-AC) is a synthetic analogue of camptothecin. Phase I studies, identified the maximum tolerated dose as 1416 micrograms/m2/day x 3 as continuous intravenous infusion (CVI) with dose-limiting neutropenia. PATIENTS AND METHODS Eligible patients had stage IIIB or IV non-small-cell lung cancer (NSCLC) with measurable disease. Patients were initially treated at 1416 micrograms/m2/d x 3 by CVI followed by granulocyte-colony stimulating factor (G-CSF) support. This dose was decreased to 1100 micrograms/m2/d after the first 13 patients. Cycles were repeated every 14 days until tumor progression. RESULTS Fifty-eight patients were treated, thirteen at 1416 micrograms/m2/d and 45 at 1100 micrograms/m2/d. Fifty percent had adenocarcinoma and 17% squamous cell carcinoma. Seventy-one percent had stage IV disease. Five patients had a partial response (response duration 9-28 weeks) for an overall response rate of 8.6%, (95% confidence intervals (CI): 2.9%-19%). Median time to progression was 2.3 months and the median survival for the entire study population 5.4 months with a one-year survival rate of 30%. The one-year survival rate for 27 patients who received second line chemotherapy was 56.7%. Toxicities at 1416 micrograms/m2/d included grade 4 neutropenia and thrombocytopenia in six and five of 13 patients, respectively; at 1100 micrograms/m2/d these toxicities were observed in 12 and three of 45 patients, respectively. CONCLUSION 9-AC has modest single-agent activity in previously untreated NSCLC. Its further evaluation at the dose and schedule employed in this study does not seem indicated. Exploration of more prolonged administration schedules may be warranted.
Collapse
Affiliation(s)
- E E Vokes
- University of Chicago, Department of Medicine, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Abstract
Munchausen's syndrome is a chronic factitious disorder characterized by frequent hospitalizations, self-inflicted injuries, and dramatic medical histories. People with this condition assume the role of a sick patient and submit to unnecessary invasive, painful, and even dangerous medical procedures. In review of the literature, there have been four reports of patients feigning oncological disease. We admitted a 27-year-old woman who had undergone operative insertion of a Port-A-Cath and multiagent chemotherapy for "advanced ovarian cancer." Physicians should be aware of Munchausen's syndrome in order to avoid costly medical procedures and unnecessary operations and to stop the patient's vicious circle of pathological lying and self-inflicted injury.
Collapse
Affiliation(s)
- A D Bruns
- Service of General Surgery, Tripler Army Medical Center, Honolulu, Hawaii 96859-5000
| | | | | | | |
Collapse
|